Newly Discovered Biomarkers May Lead to Promising Diagnostic Tool for Alzheimer’s
Approach could offer stage-specific prognosis, open door to better treatment
Diagnosing Alzheimer’s disease and determining a patient’s prognosis is an inexact business, and that stands in the way of better personalized care and advances in treatment.
First, the team of researchers discovered new physical biomarkers that could help pinpoint a diagnosis – changes to proteins found in the spinal fluid and blood of patients. In particular, as Alzheimer’s severity increased, the proteins were longer, more rigid and more clustered, said lead researcher Mingjun Zhang, a professor of biomedical engineering at Ohio State.
Click here to read more.
GOODMAN Oral Board Preparation Course Tumor
Nov. 1-3, 2017; Glendale, Ariz.
2017 Managing Coding and Reimbursement Challenges
Aug. 17-19, 2017; Chicago
2017 From Cranial to Spine: An Overview of Neurosurgical Topics for the Advanced Practice Provider
Aug. 30-Sept. 2, 2017; Chicago
Mayo Clinic Neuroscience and Oncology Innovation Summit 2017
Sept. 7-9, 2017; Orlando, Fla.
63rd Annual Meeting of the Western Neurological Society
Sept. 8-11, 2017; Banff, Alberta, Canada
Be the first to reply using the above form.